Exact Imaging, Cambridge Consultants announce plan to improve prostate cancer detection using AI

Toronto-based Exact Imaging and Cambridge, U.K.-based Cambridge Consultants have announced a new international partnership focused on improving the way specialists visualize and detect prostate cancer.

Exact Imaging’s ExactVu micro-ultrasound platform, allows urologists to assess suspicious regions and target those regions during biopsy. Cambridge Consultants, meanwhile, is using its years of experience working with artificial intelligence and deep learning, along with images secured using the ExactVu platform, to provide specialists with new and improved information.

The companies say their goal is to improve providers’ accuracy and ability to diagnose suspicious regions when treating prostate cancer patients, improving the overall quality of care.

“The need for effective management of prostate cancer is as pressing as ever,” Shweta Gupta, head of urology and women’s health at Cambridge Consultants, said in a prepared statement. “We are proud to have the opportunity to try and improve the detection pathway and excited by the opportunity to apply deep learning to this significant clinical problem.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The ACR hopes these changes, including the addition of diagnostic performance feedback, will help reduce the number of patients with incidental nodules lost to follow-up each year.

And it can do so with almost 100% accuracy as a first reader, according to a new large-scale analysis.

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.